Table 9: List of resources to be considered in the economic analysis Number of units Disaggregated unit cost Proportion of of resource per Setting in which Provider of patients relevant time resource is Other govt Private health resource receiving horizon per MBS Safety nets* Patient Total cost provided budget insurer resource patient receiving resource Resources provided to deliver BRAF V600 mutation testing – proposed scenario Block retrieval of stored sample Pathologist TBD (not all 1 TBD from tissue archive (from most samples will need recent biopsy) to be retrieved if biopsy performed at diagnosis of metastatic disease) Preparation of tissue sample Pathologist 100% 1 TBD BRAF V600 mutation molecular Molecular 100% 1 $285 - $325 TBD test pathologist Retesting if BRAF V600 status Molecular Will differ 1 $285 - $385 TBD inconclusive pathologist according to each specific test method used Resources provided to deliver drug therapy – proposed scenario Specialist consultation Medical oncologist Outpatient 47%a TBD $145.20 TBD for initiation of dabrafenib (oral) $72.65 and Regular follow-up in BRAF V600 mutation positive patients MBS 110 MBS 116 Dabrafenib Medical oncologist Outpatient/ 47%a 150 mg twice daily TBD inpatient orallyb until disease progression
Table 9: List of resources to be considered in the economic analysis Provider of resource Setting in which resource is provided Proportion of patients receiving resource Number of units of resource per relevant time horizon per patient receiving resource Disaggregated unit cost MBS Safety nets* Other govt budget Private health insurer Patient Total cost Resources provided to deliver BRAF V600 mutation testing – proposed scenario Block retrieval of stored sample from tissue archive (from most recent biopsy) Pathologist TBD (not all samples will need to be retrieved if biopsy performed at diagnosis of metastatic disease) 1 TBD Preparation of tissue sample Pathologist 100% 1 TBD BRAF V600 mutation molecular test Molecular pathologist 100% 1 $285 - $325 TBD Retesting if BRAF V600 status inconclusive Molecular pathologist Will differ according to each specific test method used 1 $285 - $385 TBD Resources provided to deliver drug therapy – proposed scenario Specialist consultation for initiation of dabrafenib (oral) and Regular follow-up in BRAF V600 mutation positive patients MBS 110 MBS 116 Medical oncologist Outpatient 47%a TBD $145.20 $72.65 TBD Dabrafenib Medical oncologist Outpatient/ inpatient 47%a 150 mg twice daily orallyb until disease progression TBD
1207-Final-DAP-accessible.docx